The applicability of soluble TRAIL in cancer therapy, however, is limited by its short half-life in vivo (Kelley et al, 2001) that may be overcome by the production of TRAIL at the tumour site by for example a nonreplicating adenoviral vector, which will also reduce the risk of hepatotoxicity (see also Griffith et al, 2000; Lin et al, 2002a). The gene discussed is TNFSF10; the disease is neoplasm.